Primary HIV infection: to treat or not to treat?

Current Opinion in Infectious Diseases
Sarah FidlerJonathan Weber

Abstract

The aim of this article is to review new data on the use of antiretroviral therapy in primary HIV infection. The concept of 'hit HIV hard and early' supporting the use of antiretroviral therapy to treat the early stages of HIV infection has been revisited. Recent demonstration of massive, rapid and largely irreversible HIV-mediated destruction of memory CD4+ T cells predominantly occurring in the gut suggests that primary HIV infection may be the only time that intervention could confer lasting immunological benefit. There are no data, however, from randomized controlled trials supporting the use of antiretroviral therapy in primary HIV infection, although a number of observational studies have demonstrated limited, transient improvements in measured immunological outcomes. The first randomized controlled trials powered to address whether antiretroviral therapy of a limited duration in primary HIV infection can influence long-term CD4 decline (SPARTAC) is now fully recruited but will report in 2-3 years. In addition, given that individuals with primary HIV infection contribute disproportionately towards onward HIV transmission, there may be an additional public health impetus for earlier diagnosis and intervention in primary HI...Continue Reading

References

Aug 17, 1995·The New England Journal of Medicine·S Kinloch-De LoësL Mathiesen
Mar 1, 1997·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·J S KoopmanK Lange
Oct 12, 2000·Nature·E S RosenbergB D Walker
Sep 15, 2001·BMJ : British Medical Journal·S FidlerJ Weber
Sep 29, 2001·BMJ : British Medical Journal·J Kaye
May 3, 2002·Nature·Daniel C DouekRichard A Koup
Oct 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Annette OxeniusRodney E Phillips
Aug 9, 2003·Nature Reviews. Drug Discovery·Andrew Carr
May 4, 2004·The Journal of Infectious Diseases·Christopher D PilcherUNKNOWN Duke-UNC-Emory Acute HIV Consortium
Sep 15, 2004·The Journal of Experimental Medicine·Jason M BrenchleyDaniel C Douek
Mar 1, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sigall KassuttoEric S Rosenberg
Apr 6, 2005·The Journal of Infectious Diseases·Maria J WawerThomas C Quinn
Jun 16, 2005·Current Opinion in Immunology·Cynthia A Derdeyn, Guido Silvestri
Jul 5, 2005·The Journal of Infectious Diseases·Jonathan LeithRalf Hinzmann
Jul 20, 2005·The Journal of Infectious Diseases·Sabine Kinloch-de LoesUNKNOWN QUEST Study Group
Jan 21, 2006·BMJ : British Medical Journal·Julie M FoxJonathan Weber
Jan 21, 2006·BMJ : British Medical Journal·Darren Walter
Jan 21, 2006·The Journal of Infectious Diseases·Richard J Hayes, Richard G White
Feb 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C Bradley HareFrederick M Hecht
Feb 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cécile GoujardUNKNOWN Agence Nationale de Recherche sur le Sida PRIMO Study Group
Jul 1, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Salvador ResinoMaria Angeles Muñoz-Fernández
Aug 15, 2006·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA panel
Aug 31, 2006·The Journal of Infectious Diseases·Hendrik StreeckMarcus Altfeld
Oct 5, 2006·Current Topics in Medicinal Chemistry·Christos Argyropoulos, Athanasia Mouzaki
Nov 17, 2006·The Journal of Infectious Diseases·Peter W Hunt, Steven G Deeks
Nov 23, 2006·Nature Medicine·Jason M BrenchleyDaniel C Douek
Dec 1, 2006·The New England Journal of Medicine·UNKNOWN Strategies for Management of Antiretroviral Therapy (SMART) Study GroupC Rappoport
Dec 7, 2006·AIDS·Mireille CentlivreBen Berkhout
Jan 5, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Souheil-Antoine YounesRafick-Pierre Sekaly
Mar 3, 2007·The Journal of Infectious Diseases·Deenan Pillay, Martin Fisher
Mar 3, 2007·The Journal of Infectious Diseases·Bluma G BrennerUNKNOWN Quebec Primary HIV Infection Study Group

❮ Previous
Next ❯

Citations

Jan 18, 2013·The New England Journal of Medicine·UNKNOWN SPARTAC Trial InvestigatorsAbdel Babiker
May 20, 2011·The New England Journal of Medicine·Myron S CohenBarton F Haynes
Oct 29, 2013·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Feb 7, 2012·Mathematical Biosciences·Vladimir P Zhdanov
Oct 16, 2010·The Journal of Emergency Medicine·Lisa E ThomasEric S Nadel
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida
Feb 28, 2009·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de expertos de Gesida y Plan Nacional sobre el Sida
May 8, 2014·Expert Review of Anti-infective Therapy·Juan AmbrosioniJose M Miro
Aug 30, 2012·International Journal of STD & AIDS·K SharrocksJ Fox
Jun 15, 2010·Current Opinion in HIV and AIDS·Elizabeth HamlynSarah Fidler
Aug 8, 2009·European Journal of Medical Research·C KoeglUNKNOWN Ac-DAG Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.